Results 81 to 90 of about 188,451 (293)
Cancer Reports, Volume 9, Issue 1, January 2026.ABSTRACT Background Hematopoietic stem cell transplantation (HSCT) is associated with significant morbidity and mortality. Frailty further increases these risks in recipients of HSCT. This systematic review analyzes the extent of frailty in patients with hematologic malignancies and patients undergoing HSCT, and explores the associations between ...
Marit Bakken +4 more
wiley +1 more source
Modelling hematopoiesis mediated by growth factors with applications to periodic hematological diseases [PDF]
, 2006 Hematopoiesis is a complex biological process that leads to the production and regulation of blood cells. It is based upon differentiation of stem cells under the action of growth factors.
Adimy, Mostafa +2 more
core +5 more sources
Beyond PD‐1/PD‐L1: New Immune Checkpoints and Therapeutic Combinations in Cancer Immunotherapy
Medicine Bulletin, Volume 2, Issue 1, Page 61-93, January 2026.ABSTRACT Recently, immune checkpoint inhibitors (ICIs), particularly PD‐1/PD‐L1 and CTLA‐4 inhibitors, have revolutionized cancer treatment, significantly improving survival rates for various malignancies. However, ICI therapies targeting single checkpoints on T cells still face numerous challenges, such as low response rates and post‐treatment ...
Yangyang Li, Zizhen Kang, Yanyun Du
wiley +1 more source
A Trib2-p38 axis controls myeloid leukaemia cell cycle and stress response signalling [PDF]
, 2018 Trib2 pseudokinase is involved in the etiology of a number of cancers including leukaemia, melanoma, ovarian, lung and liver cancer. Both high and low Trib2 expression levels correlate with different types of cancer.
Carmody, Ruaidhri J. +6 more
core +2 more sources
OTO Open, Volume 10, Issue 1, January-March 2026.Abstract Objective Recurrent acute rhinosinusitis (RARS) significantly decreases quality of life. Transplant recipients (TR) are particularly vulnerable to rhinologic conditions. There is a lack of guidelines for managing RARS in this population. Our study aims to determine the prevalence of and risk factors for RARS among TR and assess the need for ...
Estephania Candelo +2 more
wiley +1 more source
Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors [PDF]
, 2002 FLT3 mutations, either internal tandem duplications (ITDs) or aspartate residue 835 (D835) point mutations, are present in approximately one third of patients with acute myeloid leukemia (AML) and have been associated with an increased relapse rate.
Bowen, D.T. +5 more
core +1 more source
CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 1, January 2026.ABSTRACT Bosutinib is an orally available Src/Abl tyrosine kinase inhibitor and has been approved for the treatment of patients with Ph + chronic myelogenous leukemia. Bosutinib is a substrate of P‐glycoprotein (P‐gp) in vitro and is predominantly metabolized by CYP3A4 in humans with minimal urinary excretion.
Chieko Muto +2 more
wiley +1 more source
Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia [PDF]
, 2014 Chronic myeloid leukemia (CML) is a stem cell (SC) neoplasm characterized by the BCR/ABL1 oncogene. Although mechanisms of BCR/ABL1-induced transformation are well-defined, little is known about effector-molecules contributing to malignant expansion and ...
Bilban, Martin +15 more
core +1 more source
International Journal of Analytical Chemistry, Volume 2026, Issue 1, 2026.Dasatinib, a therapy for chronic myeloid leukemia, suffers from poor bioavailability. Self‐microemulsifying drug delivery systems (SMEDDSs) are used to improve its dissolution. This study aimed to develop and validate a novel reverse‐phase high‐performance liquid chromatography (RP‐HPLC) method for quantifying dasatinib in SMEDDS formulations.
Nitin V. Kokare +13 more
wiley +1 more source
Journal of Chemistry, Volume 2026, Issue 1, 2026.Reishia clavigera, an edible marine gastropod consumed in Asia and used in traditional medicine, was investigated for its secondary metabolite content. Despite its widespread consumption and ethnomedicinal use, no comprehensive study has examined the secondary metabolites from whole‐body extracts.
Yeon-Ju Lee +2 more
wiley +1 more source